Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab Plus Anlotinib in Metastatic NSCLC Post-PD-1
NCT04691388Phase 2Completed
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Mar 2021
- Primary completion
- Sep 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and anlotinib in non-small cell lung cancer (NSCLC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Overall Response Rate at 4 weeks. Started Mar 2021; status: completed.
02
Drugs
sintilimabanlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04691388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04691388.